MCE MedChemExpress

Product Data Sheet

PD-089828

Cat. No.: HY-112345

CAS No.: 179343-17-0

Molecular Formula: $C_{18}H_{18}Cl_2N_6O$ Molecular Weight: 405.28

Target: FGFR; PDGFR; EGFR; Src

Pathway: Protein Tyrosine Kinase/RTK; JAK/STAT Signaling

Storage: Powder -20°C 3 years

In solvent

4°C 2 years -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 10 mg/mL (24.67 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4674 mL	12.3371 mL	24.6743 mL
	5 mM	0.4935 mL	2.4674 mL	4.9349 mL
	10 mM	0.2467 mL	1.2337 mL	2.4674 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.56 mg/mL (1.38 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.56 mg/mL (1.38 mM); Clear solution

BIOLOGICAL ACTIVITY

Description PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR- β and EGFR (IC₅₀s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC₅₀=0.18 μM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 μM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a

long-lasting cellular activity^[1].

IC ₅₀ & Target	FGFR1 0.15 μM (IC ₅₀)	PDGFR-β 1.76 μM (IC ₅₀)	EGFR 5.47 μM (IC ₅₀)	c-Src 0.18 μM (IC ₅₀)
	FGFR1 0.14 μM (Ki)	PDGFR-β 2.38 μM (Ki)	EGFR 3.16 μM (Ki)	c-Src 0.1 μM (Ki)

In Vitro

PD-089828 (0.5-20 μ M; 2 hours) inhibits PDGFR autophosphorylation with an IC $_{50}$ of 0.82 μ M $^{[1]}$. PD-089828 (1-50 μ M; 2 hours) inhibits EGFR autophosphorylation with an IC $_{50}$ value of 10.9 μ M $^{[1]}$. In A121(p) cells, PD 089828 potently inhibits the phosphorylation of FGFR-1 with an IC $_{50}$ value of 0.63 μ M $^{[1]}$.PD-089828 (10 μ M; 8 days) produces a concentration-related inhibition of serum-stimulated cell growth with an IC $_{50}$ value of 1.8 μ M $^{[1]}$. PD-089828 inhibits increases in DNA synthesis stimulated by all three growth factors, with IC $_{50}$ values of 0.8 for PDGF-, 1.7 for EGF- and 0.48 μ M for bFGF-induced mitogenesis $^{[1]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	Vascular smooth muscle cells (serum-stimulated growth)	
Concentration:	10 μΜ	
Incubation Time:	8 consecutive days	
Result:	Produced a concentration-related inhibition of serum-stimulated cell growth with an IC50 value of 1.8 $\mu\text{M}.$	
Western Blot Analysis ^[1]		
Cell Line:	Vascular smooth muscle cells (stimulated with PDGF-BB 30 ng/ml)	
Concentration:	0.5-20 μΜ	
Incubation Time:	2 hours	
Result:	Inhibited PDGFR autophosphorylation with an IC ₅₀ of 0.82 μM.	

REFERENCES

[1]. Dahring TK, et al. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 1997 Jun;281(3):1446-56.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA